This is a working overview of Hepatocyte growth factor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Honey is a sweet and viscous substance made by several species of bees, the best-known of which are honey bees. Honey is made and stored to nourish bee colonies. Bees produce honey by gathering and then refining the sugary secretions of plants (primarily floral nectar) or the secretions of other insects, like the honeydew of aphids. This refinement takes place both within individual bees, through regurgitation and enzymatic activity, and during storage in the hive, through water evaporation that concentrates the honey's sugars until it is thick and viscous. Honey bees stockpile honey in the hive. Within the hive is a structure made from beeswax called honeycomb. The honeycomb is made up of hundreds or thousands of hexagonal cells, into which the bees regurgitate honey for storage. Other honey-producing species of bee store the substance in different structures, such as the pots made of wax and resin used by the stingless bee. Honey for human consumption is collected from wild bee colonies, or from the hives of domesticated bees. The honey produced by honey bees is the most familiar to humans, thanks to its worldwide commercial production and availability. The husbandry of bees is known as beekeeping or apiculture, with the cultivation of stingless bees usually referred to as meliponiculture. Honey is sweet because of its high concentrations of the monosaccharides fructose and glucose. It has about the same relative sweetness as sucrose (table sugar). One standard tablespoon (14 mL) of honey provides around 180 kilojoules (43 kilocalories) of food energy.
No animal species is known to be immune to the acute toxic effects of aflatoxins. Adult humans have a high tolerance for aflatoxin exposure and rarely succumb to acute aflatoxicosis, but children are particularly affected, and their exposure can lead to stunted growth and delayed development, in addition to all the symptoms mentioned below. High-level aflatoxin exposure produces an acute hepatic necrosis (acute aflatoxicosis), resulting later in cirrhosis or carcinoma of the liver. Acute liver failure is made manifest by bleeding, edema, alteration in digestion, changes to the absorption and/or metabolism of nutrients, and mental changes and/or coma. Chronic, subclinical exposure does not lead to symptoms as dramatic as acute aflatoxicosis. Chronic exposure increases the risk of developing liver and gallbladder cancer, as aflatoxin metabolites may intercalate into DNA and alkylate the bases through its epoxide moiety. This is thought to cause mutations in the p53 gene, an important gene in preventing cell cycle progression when there are DNA mutations, or signaling apoptosis (programmed cell death). These mutations seem to affect some base pair locations more than others; for example, the third base of codon 249 of the p53 gene appears to be more susceptible to aflatoxin-mediated mutations than nearby bases. As with other DNA-alkylating agents, Aflatoxin B1 can cause immune suppression, and exposure to it is associated with an increased viral load in HIV positive individuals.
== Causes == Malignant hyperthermia is a disorder that can be considered a gene–environment interaction. In most people with malignant hyperthermia susceptibility, they have few or no symptoms unless they are exposed to a triggering agent. The most common triggering agents are volatile anesthetic gases, such as halothane, sevoflurane, desflurane, isoflurane, enflurane or the depolarizing muscle relaxants suxamethonium and decamethonium used primarily in general anesthesia. In rare cases, the biological stresses of physical exercise or heat may be the trigger. In fact, malignant hyperthermia susceptibility (MHS), predisposed by mutations in the skeletal muscle calcium release channel (RYR1), is one of the most severe heat-related illnesses. The MHS-associated heat susceptibilities predominantly affect children and metabolically active young adults, often leading to life- threatening hypermetabolic responses to heat. Other anesthetic drugs do not trigger malignant hyperthermia. Some examples of drugs that don't cause MH include local anesthetics (lidocaine, bupivacaine, mepivacaine), opiates (morphine, fentanyl), ketamine, barbiturates, nitrous oxide, propofol, etomidate, and benzodiazepines. The nondepolarizing muscle relaxants pancuronium, cisatracurium, atracurium, mivacurium, vecuronium and rocuronium also are generally thought to be safe for patients MH. There is mounting evidence that some individuals with malignant hyperthermia susceptibility may develop MH with exercise and/or on exposure to hot environments.
An amputee patient in a southern Gazan hospital stated that medication comes through the crossing into Gaza every four days but its not a guarantee that patients receive medication, and that in some hospitals patients have to pay for medication and food up front. Other medications such as insulin pens were temporarily placed on restricted items to be allowed into Gaza by the Israeli government officials. This caused the UN Humanitarian Coordinator for Palestine Jamie McGoldrick to state; "On the goods that are being prohibited, it’s a full range...Some of it is medical material such as basic drugs and material for treating not just trauma but for chronic illnesses...One example would be most recently the pens that are used for insulin for children" A Canadian doctor returning from two weeks in Gaza stated he had seen the "sickest child I had ever seen in my medical career". By July 2024, children in tent camps were infected with a number of skin diseases. By the summer of 2025, Gaza's healthcare system had been sharply curtailed, with most hospitals in Gaza damaged or out of service. This makes it impossible to access even basic care and leads to growing obstacles for those in need of specialized treatment and support. The humanitarian consequences fall especially hard on children.
=== Appearance === Walls of Tarlov cysts are thin and fibrous; they are prone to rupture if touched, making surgery difficult. The nerve fibers embedded in the walls of the cysts have the appearance and size of dental floss; these nerve fibers are usually not arranged in any specific alignment. Histologic examination reveals the Tarlov-cyst outer wall is composed of vascular connective tissue, and the inner wall is lined with flattened arachnoid tissue. In addition, part of the lining containing nerve fibers also occasionally contains ganglion cells. The cysts can contain anywhere from a couple of milliliters of CSF to over 2.5 litres (0.5 imp gal; 0.7 US gal) of CSF.
Sources: en.wikipedia.org
The Kizil Caves complex is the largest of the ancient Buddhist cave sites that are associated with the ancient Tocharian kingdom of Kucha, as well as the largest in Xinjiang. Other famous sites nearby are the Kizilgaha Caves, the Kumtura Caves, Subashi Temple and the Simsim Caves. The Kizil Caves are "the earliest representative grottoes in China". At the time the caves were created, the area of Kucha was following the orthodox Sarvastivadin school of Hinayana Buddhism, although an early and minority Dharmagupta presence has also been noted. The simpler square caves may have been established by the Dharmagupta from the 4th century CE or earlier, while the "central pillar" caves, which flourished from the mid-6th century CE, can rather be associated with the Sarvastivadin school.
Another common example is the reaction of a primary amine or secondary amine with a carboxylic acid or with a carboxylic acid derivative to form an amide. This reaction is widely used, especially in the synthesis of peptides. On the simple addition of an amine to a carboxylic acid, a salt of the organic acid and base is obtained. To overcome this, the carboxylic acid first needs to be "activated". This is usually done by converting the acid into a more reactive derivative (i.e. anhydride, acid halide) or by using a coupling agent. In some cases, high temperatures (>200 °C) can overcome salt formation by driving off water, without the need for "activation" of the carboxyl group. The downside to this simple reaction is that the compounds may decompose at these elevated temperatures. The carboxylic acid derivatives can be esters, anhydrides, acid halides or any other activated species. The choice of activated carboxyl group or coupling agent can be very important in peptide synthesis, as using the wrong one can lead to racemization.
In 2007, Waters served as co-chair for the International Symposium on Dynamic Combinatorial Chemistry (November). The year after that, she was an advisory board member of International Symposia on Macrocyclic and Supramolecular Chemistry (ISMSC). In 2009, she was a guest editor for the December issue of Current Opinion in Chemical Biology. From 2009 to 2015, she was an advisory board member of International Symposia on Macrocyclic and Supramolecular Chemistry (ISMSC). In 2011, Waters was a co-organizer of the Mesilla Chemistry Workshop on "Aromatic Interactions in Chemistry and Biology"(with Ken Houk, UCLA Dept of Chemistry). In 2012, Waters was a section editor for "Supramolecular Chemistry: From Molecules to Nanomaterials" (John Wiley and Sons). In 2013, she was the co-chair, of American Peptide Society Meeting (with David Lawrence, UNC Dept of Chemistry) and a guest editor for Accounts of Chemical Research for the "Aromatic Interactions in Chemistry and Biology" article in the April issue. From 2014 to 2020, Waters was an editorial advisory board member of the Journal of the American Chemical Society.
Ralser's two research groups use LC–MS to analyze the proteomes and metabolomes of microorganisms. The main model organism is the baking yeast (Saccharomyces cerevisiae), but other species, such as pathogenic fungus Candida albicans and the fission yeast Schizosaccharomyces pombe, are used too. His lab not only uses LC–MS, but also develops novel LC–MS methods and protocols that improve detection accuracy, speed, and throughput. Specializing in data-independent acquisition, the group has developed scanning SWATH MS and Zeno SWATH MS in collaboration with MS manufacturer SCIEX. Both methods greatly improve upon SWATH MS, which was developed in Switzerland in 2012. The group additionally developed an acquisition method—DIA-NN—that uses neural networks. But proteins and metabolites are not the only focus: in 2022 the lab developed a protocol for the accurate quantification of DNA methylation using LC–MS. Key research topics include:
Walton and Torbjørn Sikkeland, used the new heavy-ion linear accelerator (HILAC) to bombard a curium target (95% 244Cm and 5% 246Cm) with 13C and 12C ions. They were unable to confirm the 8.5 MeV activity claimed by the Swedes but were instead able to detect decays from 250Fm, supposedly the daughter of 254No (produced from the 246Cm), which had an apparent half-life of ~3 s. Probably this assignment was also wrong, as later 1963 Dubna work showed that the half-life of 254No is significantly longer (about 50 s). It is more likely that the observed alpha decays did not come from element 102, but rather from 250mFm. In 1959, the Swedish team attempted to explain the Berkeley team's inability to detect element 102 in 1958, maintaining that they did discover it. However, later work has shown that no nobelium isotopes lighter than 259No (no heavier isotopes could have been produced in the Swedish experiments) with a half-life over 3 minutes exist, and that the Swedish team's results are most likely from 225Th, which has a half-life of 8 minutes and quickly undergoes triple alpha decay to 213Po, which has a decay energy of 8.53612 MeV. This hypothesis is lent weight by the fact that 225Th can easily be produced in the reaction used and would not be separated out by the chemical methods used. Later work on nobelium also showed that the divalent state is more stable than the trivalent one and hence that the samples emitting the alpha particles could not have contained nobelium, as the divalent nobelium would not have eluted with the other trivalent actinides.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.